Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
September 14, 2017 08:00 ET
|
Mustang Bio, Inc.
Entered license agreement with Fred Hutchinson Cancer Research Center for CD20-directed CAR T Initiation of Phase 1/2 investigator-initiated trial in B-cell non-Hodgkin lymphomas planned for fourth...
Mustang Bio to Present at the CAR-TCR Summit 2017
September 05, 2017 07:30 ET
|
Mustang Bio, Inc.
NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on...
Mustang Bio Commences Trading on the NASDAQ Global Market
August 22, 2017 10:15 ET
|
Mustang Bio, Inc.
NEW YORK, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on...
Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
August 14, 2017 07:30 ET
|
Mustang Bio, Inc.
NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric...
Mustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
May 15, 2017 16:05 ET
|
Mustang Bio, Inc.
NEW YORK, May 15, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric...
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
April 24, 2017 08:00 ET
|
Mustang Bio, Inc.
NEW YORK, April 24, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Manuel Litchman, M.D., has been appointed President and...
Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13Rα2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology
November 21, 2016 08:30 ET
|
Mustang Bio, Inc.
Phase 1 data suggests MB-101 is safe and well‐tolerated, capable of eliciting potent anti-tumor response NEW YORK, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress...
Mustang Bio Announces Oral Presentation of Initial Clinical Data for MB-101 (IL13Ra2-specific CAR T cells) by City of Hope Investigators at the American Society of Gene and Cell Therapy 19th Annual Meeting
May 05, 2016 09:52 ET
|
Mustang Bio, Inc.
NEW YORK, May 05, 2016 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that an oral presentation related to its MB-101 (IL13Rα2-specific...
Mustang Bio Announces Presentations of MB-101, a Novel IL13Ra2-specific CAR-T cells Product in Clinical Development, at the American Society of Gene and Cell Therapy 19th Annual Meeting
April 18, 2016 12:06 ET
|
Mustang Bio, Inc.
NEW YORK, April 18, 2016 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that two abstracts pertaining to its MB-101 (IL13Rα2-specific...